Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[2]. - The company expects a revenue guidance of RMB 1.2 billion for the full year 2023, reflecting a projected growth rate of 25%[2]. - The company's operating revenue for the first half of 2023 was ¥555,357,976.41, a decrease of 3.48% compared to ¥575,410,516.60 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2023 was ¥131,521,745.37, down 2.31% from ¥134,636,118.61 in the previous year[21]. - The company reported a total revenue of 68,134.08 million with a net profit of 2,636.29 million for the first half of 2023[58]. - The company achieved operating revenue of RMB 55,535.80 million in the first half of 2023, a decrease of 3.48% year-on-year[83]. - The net profit attributable to shareholders was RMB 13,152.17 million, down 2.31% compared to the same period last year[83]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the first half of 2023, representing a 25% year-over-year growth[153]. User Growth and Market Expansion - User data indicates a growth in the customer base by 15%, reaching a total of 1.2 million active users[2]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[2]. - User data indicates a growth in active users, reaching 10 million, which is a 15% increase compared to the previous period[154]. - Market expansion plans include entering two new international markets by Q4 2023, which is anticipated to increase market share by 10%[155]. Research and Development - Research and development expenses increased by 30%, totaling RMB 150 million, to support new technology initiatives[2]. - The company aims to accelerate the R&D and industrialization of small molecule innovative drugs and biological drugs to meet unmet clinical needs domestically and internationally[27]. - The company has 10+ Class 1 innovative drugs in development, with the oral long-acting hypoglycemic drug, Yiglitin Tablets, being the first in China to apply for Type 2 diabetes treatment, currently in Phase III clinical trials[30]. - The company is focusing on innovative biopharmaceutical research in anesthesia, oncology, and immunology, with the first-class new drug EP-9001A entering the Ib/II clinical trial phase as planned[87]. - The company is actively pursuing innovative drug development in areas such as pain management, oncology, and diabetes, leveraging advanced technologies like PROTAC[34]. - The company has ongoing research projects for new chemical drugs and biological drugs, with a total investment of 24,491.00 million in exploratory new drug research[59]. Product Development and Launches - New product launches include two innovative drugs that are expected to contribute an additional RMB 200 million in revenue by the end of the year[2]. - The company has successfully industrialized 37 high-end chemical drugs, including 5 domestic first generic products and 27 that have passed consistency evaluation[28]. - The company is expanding its product offerings with multiple high-difficulty injection products under development, having completed the production approval for 5 injection products[46]. - The company has launched multiple new products, including a compound controlled-release formulation with a production approval of 3,241.00 million and a clinical research investment of 1,274.21 million[58]. - The company is focusing on high-end generic drugs, with a total investment of 1,618.88 million in a project that has overcome significant technical challenges[61]. Financial Position and Investments - The company has maintained a strong cash position of RMB 300 million, providing flexibility for future investments[2]. - The company has reported a cumulative investment of 910.22 million in a project that has reached the production approval stage, indicating progress in its product pipeline[61]. - The company has invested 300 million in supplementary liquidity, fully utilizing the raised funds for operational needs[193]. - The total balance of guarantees to subsidiaries at the end of the reporting period was CNY 2,416.91 million, which represents 0.96% of the company's net assets[188]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[2]. - The decline in revenue and net profit was primarily due to the impact of the seventh batch of national centralized procurement on key products such as Ibandronate Sodium Injection and Caffeine Citrate Injection[21]. - The company faces risks related to national procurement policies that may lead to price reductions for some products[102]. Corporate Governance and Compliance - The board of directors confirmed that there are no significant governance issues affecting the company's operations[2]. - The company has established a commitment to avoid conflicts of interest and protect the rights of all shareholders[164]. - The company ensures that any related party transactions will be conducted at fair market prices and comply with relevant regulations[163]. Environmental Initiatives - The company has established an environmental protection mechanism and is actively investing in related initiatives[133]. - The wastewater treatment systems of Yuan Dong Bio, Qingmu Pharmaceutical, and Shode Pharmaceutical have been operating effectively without any instances of exceeding discharge standards during the reporting period[137]. - The company has taken measures to reduce carbon emissions, focusing on energy-saving practices and promoting low-carbon office methods[148]. Future Outlook - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20%[155]. - The company plans to increase its marketing budget by 30% to support new product launches and market expansion efforts[155]. - The company commits to continuous improvement in production processes and increasing investment in environmental protection equipment[147].

证券代码：688513 证券简称：苑东生物 公告编号：2023-032 成都苑东生物制药股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第三届监事会第十次会 议于 2023 年 8 月 17 日在公司会议室以现场形式召开。会议通知已于 2023 年 8 月 7 日送达全体监事。本次会议应出席监事 3 名，实际出席监事 3 名，本次会议 由监事会主席朱家裕先生主持，公司董事会秘书李淑云等列席会议。本次会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 1 在违规使用募集资金的情形。 表决结果：同意 3 票，反对 0 票，弃权 0 票。同意票占本次监事会有效表决 票数的 100%，全票表决通过。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）及指定 媒体披露的《2023 年半年度募集资金存放与使用情况的专项报告》。 经审议 ...

成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十二次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十二次会议审议的《关于 <公司 2023 年半年度募集资金存放与使用情况的专项报告>的议案》发表独立意 见如下： 报告期内，公司募集资金存放与使用情况符合《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号—— 规范运作》等法律法规和公司《募集资金管理制度》等制度文件的规定；公司对 募集资金进行了专户存储和专项使用，使用部分闲置募集资金进行现金管理事项 已履行了必要且合规的决策程序，并及时履行了相关信息披露义务，不存在变相 改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金的情形。因 此，我们一致同意该议案。 独立董事：JIN L ...

截至 2023 年 6 月 30 日止，结余募集资金（含利息收入扣除银行手续费的 净额）余额为 10,318.27 万元。具体情况如下： 单位：人民币万元 成都苑东生物制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 成都苑东生物制药股份有限公司（以下简称"苑东生物"、"本公司"或"公 司"）董事会根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规范运作》及相关格式指引的要求，编制了截至 2023 年 6 月 30 日的《2023 年半年度募集资金存放与使用情况的专项报告》。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都 苑东生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会 公开发行了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币为 44.36 元，共计募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不 含税）人民币 112,083,983.49 元，本次募集资金净额为 1,222,708,416.511元。上 ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-031 成都苑东生物制药股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）回购股份的目的和用途 风险提示： 1 拟回购股份的用途：公司拟在未来适宜时机使用本次回购的股份实施员工 持股计划或股权激励，并在股份回购实施结果暨股份变动公告披露后三年 内完成股份转让；若公司未能在规定期限内转让完毕，则将依法履行减少 注册资本的程序，未转让的股份将被注销。 拟回购价格：不超过人民币 73 元/股（含），该价格不高于公司董事会通过 回购决议前 30 个交易日公司股票交易均价的 150%。 拟用于回购股份的资金总额：不低于人民币 10,000 万元（含）且不超过人 民币 20,000 万元（含）。 回购期限：自董事会审议通过回购股份方案之日起 12 个月内。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：截至本公告披露之日，公司控股股东、实际 控制人及其一致行动人、公司董事、监事及高级管理 ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-030 成都苑东生物制药股份有限公司 第三届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第三届董事会第十一次会 议于 2023 年 8 月 14 日以现场和通讯相结合的方式召开。会议通知已于 2023 年 8 月 11 日送达全体董事。本次会议由董事长王颖主持，应出席董事 9 名，实际 出席董事 9 名。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 等相关法规和《成都苑东生物制药股份有限公司章程》规定，会议形成的决议合 法有效。 二、董事会会议审议情况 经与会董事审议，形成决议如下： （一）审议通过《关于以集中竞价交易方式回购股份方案的议案》 经审议，董事会认为：公司本次回购股份是基于对公司未来发展的信心和对 公司长期投资价值的认可，有利于充分调动公司员工的积极性，提高凝聚力，有 效地将股东利益、公司利益和员工个人利益紧密结合在一起，促进公司稳定 ...

成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十一次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十一次会议审议的《关于 以集中竞价交易方式回购股份方案的议案》发表独立意见如下： 1、公司本次回购股份符合《公司法》、《证券法》以及《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件以及《公司 章程》等有关规定，回购股份的审议和决策程序合法合规。 2、公司本次回购股份的用途为员工持股计划或股权激励，有利于充分调动 公司员工的积极性，提高团队凝聚力和竞争力，有效地将股东利益、公司利益和 员工利益紧密结合，促进公司稳定、健康、可持续发展，因此，本次股份回购具 有必要性。 3、本次回购资金来源为公司自有资金，不会对公司的经营、财务和未来发 展产生重大影响，公司 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥277,853,183.77, representing a year-on-year increase of 3.31%[5] - The net profit attributable to shareholders for the same period was ¥60,985,871.41, reflecting a growth of 13.35% compared to the previous year[5] - The basic earnings per share for Q1 2023 stood at ¥0.51, which is an increase of 13.33% year-on-year[6] - The net profit for Q1 2023 was CNY 60,985,871.41, representing an increase of 13.8% compared to CNY 53,801,911.59 in Q1 2022[19] - The operating profit for Q1 2023 was CNY 68,278,212.94, up from CNY 57,338,282.15 in the same period last year, indicating a growth of 19.4%[22] - The total operating expenses decreased to CNY 244,172,808.16 from CNY 282,959,361.73 in Q1 2022, a reduction of 13.7%[22] Research and Development - Research and development expenses totaled ¥51,336,628.31, accounting for 18.48% of operating revenue, a decrease of 1.34 percentage points from the previous year[6] - Research and development expenses increased to CNY 50,088,561.76, compared to CNY 45,192,135.02 in Q1 2022, reflecting an increase of 6.4%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥32,933,694.58, showing a decline of 11.54% compared to the same period last year[5] - The cash flow from operating activities was CNY 32,933,694.58, a decrease from CNY 37,228,404.83 in the previous year, down by 11.5%[22] - The cash flow from investment activities showed a net outflow of CNY 289,811,019.34, improving from a net outflow of CNY 512,688,220.48 in Q1 2022[23] - Cash and cash equivalents decreased to RMB 620,514,361.50 from RMB 830,966,815.87 at the end of 2022, a decline of about 25.3%[13] - The company reported a cash and cash equivalents balance of CNY 614,284,188.64 at the end of Q1 2023, compared to CNY 590,296,812.64 at the end of Q1 2022, an increase of 4.0%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period was 4,643[9] - The largest shareholder, Wang Ying, holds 41,900,000 shares, representing 34.89% of the total shares[9] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,098,765,523.95, an increase of 2.69% from the end of the previous year[6] - Current assets as of March 31, 2023, totaled RMB 1,742,813,162.60, compared to RMB 1,709,122,350.80 at the end of 2022, reflecting an increase of approximately 1.96%[13] - Total liabilities as of March 31, 2023, were RMB 592,973,210.53, up from RMB 573,080,516.96 at the end of 2022, representing an increase of about 3.2%[15] - Non-current assets totaled RMB 1,355,952,361.35, an increase from RMB 1,308,417,882.31 at the end of 2022, reflecting a growth of about 3.63%[14] - The company's retained earnings increased to RMB 881,245,083.61 from RMB 820,259,212.19 at the end of 2022, showing an increase of approximately 7.4%[15] Operating Costs - Total operating costs for Q1 2023 were RMB 226,451,481.30, slightly up from RMB 225,745,308.15 in Q1 2022, indicating a marginal increase of about 0.31%[17] - The company reported a net profit margin improvement, with total operating income growth outpacing total operating costs growth in Q1 2023[17] - The total revenue from operating activities was CNY 255,609,521.27, down from CNY 299,663,469.03 in Q1 2022, a decrease of 14.7%[22] Other Income - The company achieved other income of CNY 10,914,075.81, compared to CNY 6,027,818.28 in Q1 2022, marking an increase of 81.5%[22] - The company reported non-recurring gains of ¥14,655,333.08 for the period, after accounting for tax effects[7]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.17 billion, representing a 14.43% increase from CNY 1.02 billion in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately CNY 246.52 million, a 6.06% increase from CNY 232.43 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was approximately CNY 164.70 million, reflecting a 20.16% increase from CNY 137.07 million in 2021[23]. - The company's total assets at the end of 2022 were approximately CNY 3.02 billion, an 8.73% increase from CNY 2.78 billion at the end of 2021[23]. - The basic earnings per share for 2022 was CNY 2.05, a 5.67% increase from CNY 1.94 in 2021[24]. - The company's net assets attributable to shareholders at the end of 2022 were approximately CNY 2.44 billion, a 6.67% increase from CNY 2.29 billion at the end of 2021[23]. - The total revenue for the reporting period reached ¥60,841.99 million, with a net profit of ¥12,454.41 million, reflecting a significant increase in performance[89]. - The company achieved total revenue of CNY 1,170,512,900.63, representing a year-on-year growth of 14.43%[113]. - The net profit attributable to shareholders was CNY 246,520,800, reflecting a year-on-year increase of 6.06%[113]. Research and Development - Research and development expenses accounted for 22.65% of operating revenue in 2022, up from 20.41% in 2021[24]. - The total R&D investment for the year reached ¥265.14 million, an increase of 27.02% compared to the previous year[74]. - The proportion of R&D investment to operating income rose to 22.65%, up by 2.24 percentage points from the previous year[74]. - The company has over 10 Class 1 innovative drugs in research, with 3 currently undergoing clinical trials, including the oral long-acting hypoglycemic drug, Yograstatin tablets[50][51]. - The company is focusing on innovative drug formulation techniques, achieving a stable production process for EP-0112T, a nasal spray with significant technical challenges[91]. - The company has reported a total R&D investment of 81,481.69 million RMB, representing 29.38% of its operating revenue, which is significantly higher than the industry average[173]. - The company's R&D investment as a percentage of net assets was 10.85%, indicating a strong commitment to innovation and development[173]. - The company capitalized 12.96% of its R&D expenditures, reflecting a strategic approach to managing its research investments[173]. Market Position and Strategy - The company has a strong market position, with three of its main products ranking first in market share, including sodium namifen injection, ibuprofen injection, and ibandronic acid sodium injection[62]. - The company is focusing on building a differentiated competitive advantage in innovative drug products, particularly in the fields of anesthesia and oncology[36][37]. - The company is actively expanding its international presence, particularly in the opioid detoxification and emergency medication product lines[55]. - The company is focusing on integrating raw materials and formulations to ensure supply chain security amid global uncertainties and increasing competition in the biopharmaceutical sector[65]. - The company is strategically expanding its CMO/CDMO business to enhance profitability and strengthen its integrated supply chain capabilities[98]. - The company aims to maintain competitiveness under centralized procurement policies by enhancing operational efficiency and continuously launching new products[146]. - The company is focusing on expanding its product portfolio with new drug approvals and ongoing clinical trials for various therapeutic areas[160]. Risks and Compliance - The company has detailed various risks and countermeasures in its annual report, urging investors to pay attention to investment risks[4]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company faces risks from national volume-based procurement and medical insurance payment adjustments, which may lead to price reductions for some products[105]. - The company has implemented a complete quality management system from drug development to commercial production, ensuring strict quality control[99]. Corporate Governance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures for providing guarantees[9]. - The company has not reported any instances of more than half of the board members being unable to guarantee the authenticity of the annual report[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Internationalization and Innovation - The internationalization strategy has seen the completion of 2 ANDA submissions, with the hydrochloride injection of Nalfurafine and Nicardipine receiving priority review and acceptance from the FDA[39][40]. - The company has successfully passed the Korean MFDS certification and FDA inspections for raw materials, marking significant progress in internationalization[43]. - The company is committed to internationalization, with plans to complete five international registration projects and enhance its product pipeline for the U.S. market[198]. - The company is focusing on innovation and the development of next-generation biotechnologies to enhance its product offerings[191]. Financial Management - Government subsidies accounted for CNY 65,927,300, which is 25.16% of the total profit, indicating potential risk if policies change[112]. - Operating costs increased by 36.77% year-on-year, primarily due to higher product sales volumes[115]. - The company's investment activities generated a net cash outflow of CNY 405,702,351.20, primarily due to increased construction investments[115]. - The net cash flow from financing activities improved to ¥39,696,297.46 from -¥56,396,555.50, mainly due to increased short-term borrowings and discounted notes receivable[136]. Talent Development - The company has established a comprehensive talent development strategy, including the establishment of a Shanghai Research Institute to attract top talent and enhance innovation capabilities[46]. - The company has a research and development team of over 400 people and has established a national-level enterprise technology center and postdoctoral research workstation[95]. - The R&D personnel count increased to 407, representing 30.76% of the total workforce, with an average salary of ¥23.11 million per person[94].

证券代码：688513 证券简称：苑东生物 公告编号：2023-017 成都苑东生物制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 会议召开方式：上证路演中心网络互动 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告及 2022 年度利润分配预案，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司经营成果、财务指标等情况，公司计划 于 2023 年 04 月 21 日（星期五）上午 11:00 - 12:00 举行 2022 年度业绩暨现金分 红说明会，就投资者关心的问题进行交流，欢迎广大投资者积极参与。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及 2022 年度现金分红的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （ ...